Altamira Therapeutics Ltd. · OTC:CYTOF

Altamira Therapeutics — Auris Medical Holding — Investor Presentation (January 2018)

28 slides from Altamira Therapeutics's investor presentation, Jan 29, 2018

  1. Slide 1: Innovative Treatments for Inner Ear Disorders

    Slide 1: Innovative Treatments for Inner Ear Disorders

    Corporate Presentation January 2018 NASDAQ: EARS Innovative Treatments for Inner Ear Disorders

  2. Slide 2: Forward-looking Statements

    Slide 2: Forward-looking Statements

    1 Forward - looking Statements This presentation and the accompanying oral commentary contain “forward - looking” statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation and the accompanying o ral commentary

  3. Slide 3: Key Investment Highlights

    Slide 3: Key Investment Highlights

    Key Investment Highlights 2 www.aurismedical.com | NASDAQ: EARS Keyzilen ® for Acute Inner Ear Tinnitus: fast track designation Expect Phase 3 results in Q1 2018 3 Addressing the “Big 3” neurotology disorders with targeted - delivery products Hearing loss, Tinnitus and V ertigo 1 AM - 111 for Acute

  4. Slide 4: Dedicated to Developing Neurotologic Therapeutics

    Slide 4: Dedicated to Developing Neurotologic Therapeutics

    3 Dedicated to Developing Neurotologic Therapeutics • Headquartered in Switzerland • Founded in 2003 • IPO in August 2014 • NASDAQ: EARS • Shares outstanding: 48.7M • Market cap: ~ $25M www.aurismedical.com | NASDAQ: EARS

  5. Slide 5: Leadership Team Brings Significant Industry Experience

    Slide 5: Leadership Team Brings Significant Industry Experience

    Leadership Team Brings Significant Industry Experience Thomas Meyer, PhD Founder, Chairman and CEO • Former CEO and BoD member of diabetes care company Disetronic , >3B CHF market cap • Instrumental in Disetronic’s IPO and managing >20% sales CAGR over many years Hernan Levett , CPA Chief Financial

  6. Slide 6: Robust Pipeline of Innovative Neurotologic Treatments

    Slide 6: Robust Pipeline of Innovative Neurotologic Treatments

    Robust Pipeline of Innovative Neurotologic Treatments 5 www.aurismedical.com | NASDAQ: EARS Dates of key milestones are indicative and subject to change.

  7. Slide 7: Key Upcoming Milestones

    Slide 7: Key Upcoming Milestones

    6 Key Upcoming Milestones www.aurismedical.com | NASDAQ: EARS Q1 2018 • Announce TACTT3 top - line results • Start second AM - 125 Phase 1 trial Q2 2018 • Discussions on AM - 111 regulatory pathway • Complete AM - 125 Phase 1 trial • IND for AM - 125 Fall 2018 • Start AM - 125 Phase 2 trial

  8. Slide 8: Keyzilen (AM-101) for Tinnitus

    Slide 8: Keyzilen (AM-101) for Tinnitus

    7 www.aurismedical.com | NASDAQ: EARS Keyzilen (AM - 101) for Tinnitus AM - 125 for Vertigo AM - 111 for Hearing Loss

  9. Slide 9: Acute Inner Ear Tinnitus

    Slide 9: Acute Inner Ear Tinnitus

    Acute Inner Ear Tinnitus 8 • Unpleasant, unwanted sensation often perceived as “ringing” in the ears • Similar to pain sensation • Significant impact on sleep and ability to concentrate or relax • Substantial emotional distress and reduced quality of life • Acute stage = first three months • Current

  10. Slide 10: Keyzilen Targets Aberrant NMDA Receptor Activity

    Slide 10: Keyzilen Targets Aberrant NMDA Receptor Activity

    Keyzilen Targets Aberrant NMDA Receptor Activity 9 www.aurismedical.com | NASDAQ: EARS • Noise overexposure causes acute injury of the inner ear • Keyzilen’s API, Esketamine , is a potent NMDA receptor antagonist • Inhibits aberrant NMDA mediated exitation of auditory nerve which is perceived as tin

  11. Slide 11: Proof of Concept in Two Phase Trials

    Slide 11: Proof of Concept in Two Phase Trials

    Proof of Concept in Two Phase 2 Trials 10 www.aurismedical.com | NASDAQ: EARS • Gradual and statistically significant improvement in tinnitus loudness (TLQ) and other PROs: • Tinnitus annoyance • Sleep difficulties • Tinnitus impact • Patients treated within first three months from tinnitus onset (=

  12. Slide 12: First Phase 3 Not Meeting Expectations, But...

    Slide 12: First Phase 3 Not Meeting Expectations, But...

    11 • TACTT2 trial did not meet co - primary endpoints: change in TLQ and TFI • Potential design issue related to daily TLQ (patients focusing more on tinnitus, rating fatigue) • TFI performing better than TLQ • Clinically meaningful TFI improvement in relevant subgroups of patients with otitis media

  13. Slide 13: Heading Into TACTT3 Read-Out

    Slide 13: Heading Into TACTT3 Read-Out

    Heading Into TACTT3 Read - Out 12 Applying key learnings from TACTT2 to its European sister trial TACTT3 • Protocol amendment in 2016 while still fully blinded • Elevated change in TFI to single primary efficacy endpoint • Enhanced statistical power by enrolling additional patients in each stratum •

  14. Slide 14: Keyzilen: $750 Million US Market Potential

    Slide 14: Keyzilen: $750 Million US Market Potential

    Keyzilen: $750 Million US Market Potential 13 www.aurismedical.com | NASDAQ: EARS  53 US ENT doctors surveyed 1 • 41 general ENTs, 12 otologists  See an average of 44 tinnitus patients per month  Target label: acute peripheral tinnitus following traumatic injury to the cochlea or otitis media • P

  15. Slide 15: AM-125 for Vertigo

    Slide 15: AM-125 for Vertigo

    14 www.aurismedical.com | NASDAQ: EARS Keyzilen (AM - 101) for Tinnitus AM - 125 for Vertigo AM - 111 for Hearing Loss

  16. Slide 16: About Vertigo

    Slide 16: About Vertigo

    15 About Vertigo • False sensation of movement • Perceived as spinning or wheeling sensation • Potential for imbalance, nausea or vomiting • Peripheral causes include: • Functional: Meniere’s disease, labyrinthitis • Neurosensory : vestibular neuritis • Mechanical: benign paroxysmal positional verti

  17. Slide 17: Betahistine Targets Histamine Receptors

    Slide 17: Betahistine Targets Histamine Receptors

    16 Betahistine Targets Histamine Receptors • Betahistine is a histamine analogue • H 1 receptor agonist • H 3 receptor antagonist • Both receptors widely expressed in brain and inner ear • Betahistine is used to treat vertigo by increasing • cochlear and vestibular blood flow ( peripheral ) • metabo

  18. Slide 18: AM-125 Market Opportunity

    Slide 18: AM-125 Market Opportunity

    17 AM - 125 Market Opportunity • ~35% of US adults over 40 years old (69 million Americans) have experienced some form of vestibular dysfunction 1 • Almost 4 million ER visits p.a. related to dizziness or vertigo 2 • Oral betahistine is one of the most widely - used medications for treating vertigo

  19. Slide 19: AM-111 for Hearing Loss

    Slide 19: AM-111 for Hearing Loss

    18 www.aurismedical.com | NASDAQ: EARS Keyzilen (AM - 101) for Tinnitus AM - 125 for Vertigo AM - 111 for Hearing Loss

  20. Slide 20: Acute Inner Ear Hearing Loss

    Slide 20: Acute Inner Ear Hearing Loss

    Acute Inner Ear Hearing Loss 19 • Loss of sound perception • Significant impact on cognitive and auditory function • Substantially reduced quality of life • Acute stage = first four weeks • Oral corticosteroids de facto standard of care despite lack of evidence for efficacy 1 • Poor prognosis for ac

  21. Slide 21: AM-111 Protects Stress Injured Sensory Cells

    Slide 21: AM-111 Protects Stress Injured Sensory Cells

    AM - 111 Protects Stress Injured Sensory Cells 20 • C - jun N - terminal Kinase (JNK) involved in various cochlear insults • Stress conditions and pro - inflammatory cytokines activate JNK • AM - 111 is a potent cell - penetrating JNK inhibitor peptide protecting against apoptosis and inflammation •

  22. Slide 22: Significant Hearing Improvement in Phase 3 Subpopulation

    Slide 22: Significant Hearing Improvement in Phase 3 Subpopulation

    21 Significant Hearing Improvement in Phase 3 www.aurismedical.com | NASDAQ: EARS Profound acute hearing loss (≥ 90 dB) at baseline 0.018 0.016 0 5 10 15 20 25 30 35 40 45 50 Day 3 Day 7 Day 28 Day 91 AM-111 0.4 mg/mL AM-111 0.8 mg/mL Placebo Improvement of hearing threshold at the average of the th

  23. Slide 23: AM-111: $400 Million US Market Potential

    Slide 23: AM-111: $400 Million US Market Potential

    AM - 111: $400 Million US Market Potential 22 www.aurismedical.com | NASDAQ: EARS  53 US ENT doctors surveyed 1 • 41 general ENTs, 12 otologists  See an average of 11 patients with sudden deafness and 6 patients with acute acoustic trauma per month • Primary Market Research • Market Potential 40%

  24. Slide 24: Key Strategy Elements

    Slide 24: Key Strategy Elements

    Key Strategy Elements 23 www.aurismedical.com | NASDAQ: EARS Emerge as first neurotology company to bring first - in - class products to market Retain rights in US & EU Selectively partner in Asia and other regions Build commercial organization to serve ENTs with highly synergistic products Expand p

  25. Slide 25: Financial Overview

    Slide 25: Financial Overview

    Financial Overview 24 www.aurismedical.com | NASDAQ: EARS • 2018 operating expenses estimated at CHF 18m • Decreasing over 2017 as phase 3 trials completed / completing • Only partly compensated by increasing spending on AM - 125 • Declining sequentially through 2018 • Funding with cash on hand up t

  26. Slide 26: Ownership / Capitalization

    Slide 26: Ownership / Capitalization

    25 Ownership / Capitalization www.aurismedical.com | NASDAQ: EARS O WNE R S H IP T AB L E a s of Jan 23, 2018 Hold e r # of Com m on S h a re s % of Com m on S h a re s 5% Hol d e r s Sofinnova Venture 7,818,175 16.06 % Sofinnova Capital 5,384,450 11.06 % T o t al o w ne r s hip > 5 % 15,702,625 27

  27. Slide 27: Key Takeaways

    Slide 27: Key Takeaways

    26 Key Takeways www.aurismedical.com | NASDAQ: EARS Unmet medical need, serious conditions, safe treatments Targeting three major disorders: tinnitus, hearing loss and vertigo No FDA approved products Late stage pipeline Large US and global market opportunity in inner ear disorders Major news flow i

  28. Slide 28: Auris Medical Holding AG

    Slide 28: Auris Medical Holding AG

    Auris Medical Holding AG Bahnhofstrasse 21 CH - 6300 Zug Tel. +41 41 729 71 94 | Fax +41 61 201 13 51 www.aurismedical.com | NASDAQ: EARS Take care of your ears!

Source: SEC EDGAR · 6-K filed Jan 29, 2018

More decks from Altamira Therapeutics Ltd.

All 7 Altamira Therapeutics decks